Overweight adolescents with high fasting blood sugar at higher risk of subclinical atherosclerosis

Previous studies have suggested the association of incident diabetes with higher carotid intima-media thickness, coronary artery calcium scores ⩾of 400, and incident cardiovascular events.

According to a study published in Jornal de Pediatria, researchers have concluded that Adolescents who are overweight and exhibit elevated fasting blood sugar levels face an increased risk of subclinical atherosclerotic disease or SAD.
This Cross-sectional study included 161 adolescents aged 10-19 years with a BMI of ≥ +1 z-Score. To assess subclinical atherosclerotic disease, ultrasound was used to evaluate IMT (Carotid intima-media complex thickness).
The cardiometabolic indicators were age, sex, nutritional status, central adiposity, blood pressure, lipid profile, and glycemic profile. The data was presented using central tendency, dispersion measures, and absolute and relative frequency.
Pearson or Spearman correlation and multiple regression modelling determined the relationship between IMT measurement and other variables and predictors of IMT.
Key findings from the study are:
23.7 % had Carotid thickening.
The prevalence of abnormal fasting glucose was the lowest.
Age and fasting glucose were predictors of IMT increase.
IMT decreased by 1 % with age yearly and increased by 0.24 % per mg/dL with glucose.
They said the main objective of our study was to build a model based on cardiometabolic indicators, allowing the identification of overweight adolescents at higher risk of SAD. We found adolescents at higher risk are younger with higher fasting glycemia levels.
Reference:
Medeiros, Camila M., et al. “Fasting Glucose: a Cardiometabolic Indicator for Subclinical Atherosclerosis On Excess Weight Adolescents.” Jornal De Pediatria, 2024.

Powered by WPeMatico

ADB approves Rs 4k crores loan to boost health infrastructure in Maharashtra

Thane: Maharashtra Chief Minister Eknath Shinde on Monday said the Asian Development Bank will provide loan of Rs 4,000 crore to improve medical facilities in the state.

The in principle approval for the first tranche of Rs 1,200 crore has been given, he added.

“The Asian Development Bank has sanctioned the pending proposal of Rs 4000 crore loan to Maharashtra for creating advanced healthcare infrastructure and medical education. It has also given in-principle approval for Rs 1,200 crore in the first phase,” the CMO said in a statement.

Also Read:Over Rs 112 crore financial aid to over 13000 patients in just 14 months in Maha: Official

It said the CM had instructed officials to start work on a 500-bed hospital in Dharashiv (formerly Osmanabad).

“The ADB has suggested seven different types of improvements at administrative level as well as in medical education. It includes centre of excellence, digital medical education and health policy, e-hospital, encouragement to medical officers and staff, property management, sustainability policy, recruitment centres, decentralisation of medicine procurement,” it said.

“The ADB would be giving Rs 1,200 crore for construction of the hospital. The tender procedure for construction of similar infrastructure at Alibaug in Raigad district is completed while process for Kolhapur and Sindhudurg is going on,” the release quoted him as saying.

Speaking after inaugurating a super speciality hospital in Ulhasnagar in Thane, Shinde his government aimed to start a medical college and super speciality hospital in every district.

Shinde hailed the cashless hospitalisation system prevalent in Thane and said he would take efforts to replicate it across the state.

Shinde also said he had carried out the “biggest surgery in the state” as everything was in a bad state, a reference to his rebellion in June 2022 which brought down the Uddhav Thackeray-led Maha Vikas Aghadi government.

Powered by WPeMatico

Many Adults and kids may report shortness of breath after recovery from COVID-19 infection: Study

Research evidence describes new and persistent symptoms and conditions as potential post-acute sequelae of SARS-CoV-2 infection (PASC).

In their recent investigation, Yongkang Zhang et al. and colleagues concluded that hospitalized SARS-CoV-2 patients are at higher risk of developing specific symptoms and conditions following acute infection. This study is published in BMC Infectious Diseases.
In this retrospective investigation, scientists analyzed the prevalence of particular symptoms and conditions linked to COVID-19 as potential post-acute sequelae of SARS-CoV-2 infection occurring between 31 to 150 days after a SARS-CoV-2 test in both adults and children with positive and negative test outcomes.
The study used data from electronic health records (EHR) from 43 PCORnet sites participating in a national COVID-19 surveillance program. It involved over 3 million adults and over 675,000 children who underwent a SARS-CoV-2 laboratory test between March 1, 2020, and May 31, 2021, as recorded in their HER. Logistic regression and Cox models were used to calculate the risk and estimate the odds of having symptoms.
Key findings of the study are:
  • Out of 3,091,580 adults, 316,249 were SARS-CoV-2 positive, and 2,775,331 were negative.
  • Among 675,643 children, 62,131 were positive and 613,512 negative.
  • Hospitalized adults and children who had positive tests had increased odds of being diagnosed with more than 1 symptom, with aOR of 1.17 and 1.18 for adults and children, respectively.
  • The aOR for shortness of breath in adults and children were 1.50 and 1.40, respectively, 31–150 days following a SARS-CoV-2 test when compared to those who were hospitalized individuals with a negative test.
  • Hospitalized adults with a positive test had a higher risk of being diagnosed with ≥ 3 symptoms or fatigue.
  • Among hospitalized adults with a positive test, there were higher risks of being newly diagnosed with type 1 or type 2 diabetes, haematological disorder or respiratory disease with aHR of 1.25, 1.19 and 1.44, respectively.
  • Non-hospitalized adults with a positive test also had a greater risk of being diagnosed with specific symptoms or conditions.

We observed that variations in symptoms and conditions after SARS-CoV-2 infection were more pronounced among hospitalized patients than non-hospitalized individuals. This aligns with previous literature indicating that individuals with severe acute SARS-CoV-2 infection, such as those requiring hospitalization, are at increased risk of experiencing post-acute sequelae of SARS-CoV-2 infection (PASC) symptoms and conditions.

The results of this study have both clinical and public health implications, they added.
Study limitations include underestimating and underestimating prevalence and symptoms using EHR data, different lengths of baseline periods, lower specificity, and non-inclusion of covariates, such as vaccination status.
Reference:
Zhang, Y et al. Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults. BMC Infect Dis 24, 181 (2024). https://doi.org/10.1186/s12879-024-09076-8

Powered by WPeMatico

Breakthrough Treatment Offers Hope for Electrical Storm Patients

In
a groundbreaking effort to address the clinical emergency posed by electrical
storms (ES) and the scarcity of effective treatments, researchers have unveiled
compelling findings from the STAR study, a multicenter observational
investigation. The study focused on the potential efficacy and safety of
percutaneous stellate ganglion block (PSGB) as a novel intervention for ES,
refractory to standard treatments. The results, spanning the period from July
1, 2017, to June 30, 2023, present a ray of hope for patients grappling with
this challenging condition.

The
study results were published in the European Heart Journal.

Electrical
storms, characterized by three or
more episodes of ventricular arrhythmias or ventricular fibrillation (VF),
represent a critical clinical scenario with limited established therapeutic
options. Initial reports on PSGB hinted at its safety and effectiveness, but
questions lingered, prompting the need for a comprehensive study. The STAR
study aimed to fill this void, shedding light on the potential of PSGB as a
viable intervention for ES.

Conducted
as a multicenter observational study, STAR enrolled 131 patients from 19
centers, all experiencing ES refractory to standard treatments. The primary
focus was on assessing the reduction of treated arrhythmic events by at least
50%, comparing the 12 hours following PSGB with the 12 hours preceding the
procedure. Operators underwent specialized training for both the anterior
anatomical and lateral ultrasound-guided approaches.

Key
Findings:

  • The results of the STAR study are nothing short of promising.
  • Among the 184 PSGB procedures conducted, 92% of patients achieved the primary outcome, showcasing a significant reduction in arrhythmic events.
  • The median reduction of arrhythmic episodes between 12 hours before and after PSGB was an impressive 100%, underscoring the potential efficacy of this intervention.
  • Importantly, arrhythmic episodes requiring treatment exhibited a noteworthy decline, with a statistically significant difference observed between the 12 hours before the first PSGB and the 12 hours after the last procedure.
  • The reduction continued when comparing 1 hour before and 1 hour after each procedure, emphasizing the sustained impact of PSGB.
  • Moreover, the study reported a low incidence rate of one major complication, emphasizing the safety profile of the intervention.

The
STAR study marks a significant stride in the pursuit of effective treatments
for electrical storms. The compelling evidence supporting the effectiveness and
safety of PSGB in treating refractory ES offers newfound hope for patients and
clinicians alike. These findings pave the way for further exploration and
potential incorporation of PSGB into the standard armamentarium for managing
this complex clinical emergency.

Further reading: Savastano S, Baldi E, Compagnoni S, et al. Electrical storm treatment by percutaneous stellate ganglion block: the STAR study. Eur Heart J. Published online January 30, 2024. doi:10.1093/eurheartj/ehae021

Powered by WPeMatico

Higher dietary niacin consumption tied to 30% lower risk of all-cause mortality among NAFLD patients

There is a lack of Evidence on the effect of dietary niacin intake on the mortality risk among patients with NAFLD.

An Original Investigation on Global Health published in JAMA Network Open has concluded that patients with nonalcoholic fatty liver disease (NAFLD) may benefit from increased dietary niacin intake.
This study investigated the relationship between dietary niacin intake and all-cause and CVD mortality among individuals with NAFLD. The analysis included data from the National Health and Nutrition Examination Survey between 2003 and 2018, and 4,315 adults aged 20 or older with NAFLD were included in the study.
Key points from the study are:
· This study analyzed 4315 participants with a mean age of 52.5 years
· 1670 participants≥60 years of age, and 2351 were men.
· Over 560 deaths were recorded during an average follow-up of 8.8 years, with 197 attributed to CVD.
· Among NAFLD patients, the Participants with higher niacin intake (26.7 mg or more) had lower all-cause mortality risk compared to those with lower niacin intake (18.4 mg or less),
· The adjusted hazard ratios for individuals with higher niacin intake for all-cause mortality and CVD risk were 0.70 and 0.65, respectively,
This study of US adults with NAFLD indicates that a higher intake of niacin through diet may be linked to a lower risk of all-cause mortality among individuals with NAFLD but not with lower CVD mortality risk. More research is needed to determine the ideal intake levels for niacin to reduce all-cause and CVD mortality risk among NAFLD patients.
Reference:
Pan J, Zhou Y, Pang N, Yang L. Dietary Niacin Intake and Mortality Among Individuals With Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2024;7(2):e2354277.
doi:10.1001/jamanetworkopen.2023.54277

Powered by WPeMatico

Evolocumab reduces major adverse cardiovascular events in patients with and without multivessel disease: FOURIER

USA: The PCSK9 inhibitor evolocumab significantly reduces the rate of major adverse cardiovascular events (MACEs) in patients with and without multivessel coronary artery disease (MVD), according to a new analysis of FOURIER and its open-label extension study. The findings were published online in the Journal of the American College of Cardiology.

“The magnitude of effect with evolocumab was about twice as large in those who had multivessel disease, benefit emerged early and grew larger over time in this higher-risk subgroup,” the researchers reported.

“In those without MVD, the treatment effect was observed roughly after one year and did become larger during extended follow-up.”

In the FOURIER, risk reduction for MACEs with evolocumab was greater in patients with multivessel disease, during a median follow-up of 2.2 years. The FOURIER Open-Label Extension (FOURIER-OLE) provides an additional median follow-up of 5 years.

Daniel J. McClintick, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA, and colleagues aimed to assess the long-term benefit of evolocumab in patients with and without MVD.

FOURIER randomized 27,564 patients to evolocumab versus placebo; 6,635 entered FOURIER-OLE. Based on the presence of MVD (≥40% stenosis in ≥2 large vessels), patients with coronary artery disease (CAD) were categorized.

The new study included patients in FOURIER and FOURIER-OLE, the open-label extension study including those initially randomized to evolocumab continued on treatment as well as placebo-treated patients who switched to evolocumab. At the start of FOURIER, 6,007 had an MVD and 17,649 had CAD without multivessel disease.

The median follow-up of FOURIER was 2.2 years, but the 5,887 patients who entered FOURIER-OLE were followed for an additional 5.0 years. The median and maximum follow-up for the analysis were 7.1 and 8.6 years, respectively.

The primary endpoint of the study was myocardial infarction, cardiovascular death, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary endpoint was myocardial infarction, cardiovascular death, or stroke.

Key findings were as follows:

  • Of 23,656 patients in FOURIER with CAD, 25.4% had MVD; 5,887 patients continued into FOURIER-OLE.
  • The risk reduction with initial allocation to evolocumab tended to be greater in patients with MVD than in those without 23% (HR: 0.77) versus 11% (HR: 0.89) for the primary and 31% (HR: 0.69) versus 15% (HR: 0.85) for the key secondary endpoints.
  • The magnitude of benefit tended to grow during the first several years, reaching 37% to 38% reductions in risk in patients with MVD and 23% to 28% reductions in risk in patients without MVD.

The findings showed a reduction in MACE rates with evolocumab in patients with and without MVD. The benefit tended to occur earlier and was larger in patients with MVD. However, in both groups, the magnitude grew over time.

“These data support early initiation of intensive low-density lipoprotein cholesterol lowering both in patients with and without multivessel disease,” the researchers concluded.

Reference:

McClintick DJ, O’Donoghue ML, De Ferrari GM, Ferreira J, Ran X, Im K, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Atar D, Keech A, Giugliano RP, Sabatine MS. Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. J Am Coll Cardiol. 2024 Feb 13;83(6):652-664. doi: 10.1016/j.jacc.2023.11.029. PMID: 38325990.

Powered by WPeMatico

Ipragliflozin treatment improves blood sugar control avoiding ketoacidosis in patients with type 1 diabetes

Japan: Ipragliflozin treatment for type 1 diabetes (T1D) may help improve glycaemic control/variability while avoiding ketoacidosis, according to findings from a multicentre, open-label, prospective study published in Diabetes, Obesity and Metabolism.

The study stated that using SGLT2 inhibitor ipragliflozin for T1D increased postprandial glucagon secretion, which did not exacerbate postprandial hyperglycaemia but might protect against hypoglycaemia, leading to reduced glycaemic variability. The increased secretion of glucagon might accelerate ketogenesis when adequate insulin is not supplied.

Intensive insulin therapy remains the mainstay treatment for T1D, including multiple daily injections with different formulations and insulin pumps. However, intensive insulin therapy can raise the risks of weight gain and hypoglycaemia. Recent advances in insulin formulations, continuous glucose monitoring (CGM) systems, and insulin delivery systems have helped improve glycemic control in T1D patients. However, it is still difficult to keep glucose levels within the normal range without increasing the risks of weight gain and hypoglycaemia even when these new technologies are used. So, there is a demand for additional therapies to supplement insulin treatment that can achieve optimal glycaemic control for patients with T1D.

Clinical trials have shown the efficacy of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes by significant reductions in glycemic variability and body weight, but elevated susceptibility to ketoacidosis via elevated glucagon secretion was a potential concern.

The Suglat-AID evaluated glucagon responses and their associations with glycaemic control and ketogenesis before and after type 1 diabetes treatment with the sodium-glucose cotransporter 2 inhibitor, ipragliflozin.

Yuta Nakamura, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, and colleagues included adults with type 1 diabetes (n=25) who took 50-mg open-labelled ipragliflozin daily as adjunctive to insulin. Clinical/laboratory data, including continuous glucose monitoring, were collected until 12 weeks following the ipragliflozin initiation.

The participants underwent a mixed-meal tolerance test (MMTT) twice [before (first MMTT) and 12 weeks after ipragliflozin treatment (second MMTT)] to evaluate responses of glucose, glucagon, C-peptide, and β-hydroxybutyrate.

The study led to the following findings:

  • The area under the curve from fasting (0 min) to 120 min (AUC0-120min) of glucagon in the second MMTT was significantly increased by 14% versus the first MMTT.
  • The fasting and postprandial β-hydroxybutyrate levels were significantly elevated in the second MMTT versus the first MMTT.
  • The positive correlation between postprandial glucagon secretion and glucose excursions observed in the first MMTT disappeared in the second MMTT, but a negative correlation between fasting glucagon and time below range (glucose, <3.9 mmol/L) appeared in the second MMTT.
  • The percentage changes in glucagon levels (fasting and AUC0-120min) from baseline to 12 weeks were significantly correlated with those in β-hydroxybutyrate levels.

The study showed that an adjunctive treatment of ipragliflozin in type 1 diabetes patients increased postprandial glucagon secretion but improved postprandial hyperglycaemia with a decrease in glycaemic variability. The increased secretion of glucagon might contribute to reduction of glycemic variability and hypoglycaemia without causing postprandial hyperglycaemia.

The elevated postprandial glucagon might indirectly or directly affect ketone production under the condition of insulin insufficiency.

“Our findings may support the proper use of ipragliflozin to improve glycaemic variability/control and avoid ketoacidosis in patients with T1D,” they concluded.

Reference:

Nakamura Y, Horie I, Kitamura T, Kusunoki Y, Nishida K, Yamamoto A, Hirota Y, Fukui T, Maeda Y, Minami M, Matsui T, Kawakami A, Abiru N. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15458. Epub ahead of print. PMID: 38253809.

Powered by WPeMatico

Acupuncture may curb heightened risk of stroke associated with rheumatoid arthritis BMJ study

A course of acupuncture may curb the heightened risk of stroke associated with rheumatoid arthritis, finds a comparative study published in the open access journal BMJ Open.

The effects seem to be independent of sex, age, medication use, and co-existing conditions, the findings indicate, prompting the researchers to suggest that the procedure may reduce levels of pro-inflammatory proteins (cytokines) in the body that are linked to cardiovascular disease.

The principal cause of death in people with rheumatoid arthritis is cardiovascular disease. And they are more likely to have a stroke than the general population, note the researchers.

Acupuncture is already used to control pain and dampen down inflammation, and the researchers wanted to find out if it might also lower the risk of ischaemic stroke–caused by a blood clot in the brain-that is associated with systemic inflammation.

They drew on national medical records from the Registry for Catastrophic Illness Patients Database (RCIPD), for 47,809 adults newly diagnosed with rheumatoid arthritis between 1997 and 2010.

The final analysis included 23,226 patients with complete data, 12,266 of whom were treated with acupuncture following their diagnosis up until the end of December 2010.

Of these, 11,613 were each matched for age, sex, co-existing conditions-diabetes, high blood pressure, high blood fats, congestive heart failure, anxiety/depression, obesity, atrial fibrillation, alcohol dependency, and smoking-medication use-non-steroidal anti-inflammatory drugs, statins, and disease modifying drugs-and year of diagnosis with a patient who hadn’t been treated with acupuncture.

Women, those aged 40–59, and participants with high blood pressure predominated in both groups.

Most (87%) of those in the acupuncture group were treated with manual acupuncture (87%); 3% were treated with electroacupuncture, whereby an electrode producing a low pulse of electricity is attached to the needle; and 10% received both types.

On average, 1065 days elapsed between a rheumatoid arthritis diagnosis and receipt of the first acupuncture treatment, with the number of treatments averaging around 10 in total.

During the monitoring period up to the end of 2011, 946 patients had an ischaemic stroke. Unsurprisingly, risk rose in tandem with increasing age, and with the number of co-existing conditions.

Those with high blood pressure, for example, were more than twice as likely to have a stroke as those with normal blood pressure, while those with diabetes were 58% more likely to do so.

But there were significantly fewer cases of ischaemic stroke among the acupuncture group: 341 vs 605, equivalent to a 43% lower risk. And this was independent of age, sex, medication use, and co-existing conditions.

This is an observational study, and as such, no firm conclusions can be drawn about cause and effect, and the researchers also acknowledge that they were only able to estimate disease severity from the drugs the patients took.

Nor did they have information on potentially influential factors, such as height, weight, lab tests or physical activity levels, and not everyone would have had the same pressure points needled, they add.

But they point out: “Inflammation is a consistent and independent predictor of cardiovascular disease in [rheumatoid arthritis],” so acupuncture may lower pro-inflammatory proteins, thereby reducing the risk of cardiovascular disease, including ischaemic stroke, they suggest.

“Unstable blood pressure and lipid profiles are the two risk factors for ischaemic stroke, and acupuncture therapy has the advantage of controlling both hypertension and dyslipidaemia,” they explain, adding: “If acupuncture relieves morning stiffness and joint pain, patients might also benefit from increasing daily activities, which might also reduce the risk of stroke.”

Reference:

http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2023-075218

Powered by WPeMatico

Why ventilators can be tough on preemie lungs

Many premature infants need mechanical ventilation to breathe. However, prolonged ventilation can lead to problems like respiratory diseases or ventilation-induced injury.

Jonas Naumann and Mareike Zink study the physics of mechanical stress from ventilation at Leipzig University, in Leipzig, Germany and discovered some of the mechanisms that explain why premature lungs are especially sensitive to stress. Naumann will present their research at the 68th Biophysical Society Annual Meeting, to be held February 10 – 14, 2024 in Philadelphia, Pennsylvania.

When you breathe normally, your diaphragm and the muscles between ribs create a negative pressure inside the lung. “But when you are undergoing mechanical ventilation, you are creating hydrostatic overpressure. And the forces which are acting during mechanical ventilation are completely different than during normal breathing. And this is probably causing some kind of damage to the cells,” Zink explained.

Using lung tissue from fetal and adult rats, the researchers together with collaborators from the Division of Neonatology, University Clinic Leipzig, used varying amounts of tension with rest phases in between, similar to the actions that occur within the lung during mechanical ventilation. Even with a little pressure, the premature rat lung tissue showed characteristics of being both elastic and viscous. This means the lung tissue changed its shape and responded to stress in a way that wasn’t normal. Moreover, they found that “the fetal lung is much stiffer than the adult lung under deformation,” said Naumann.

To determine whether these tension-related changes in the tissue led to alterations in sodium transport, which is important for removing the water from the lungs that is present at birth, the team used electrophysiology to measure the movement of ions across a layer of premature lung cells. They found that changes in pressure affected the activity of two channels involved in sodium transport-the epithelial sodium channel and the sodium-potassium ion pump in the cells of lung alveoli. This disruption in the normal function of these transporters could explain why mechanical ventilation has negative effects on the infant’s lungs.

“This may be the reason why lung fluid cannot get absorbed that well into the circulation after the preterm births,” Naumann explained. He hopes that there will be more research about what ventilator settings might lead to the best outcomes for preemies. Naumann points out that “small pressure gradients can have such a big impact on the lung mechanics.”

The next phase of their research will be exploring how the lung tissue’s extracellular matrix, the scaffolding and the glue that holds cells together, plays a role in mechanical ventilation. By better understanding how the premature lung responds to pressure, they hope that future studies improve therapies for babies born early.

Powered by WPeMatico

Melatonin significantly increases efficacy of full-mouth scaling and root planing in patients with diabetes and periodontitis

In a groundbreaking clinical study
addressing the intricate relationship between diabetes mellitus (DM) and
periodontitis, researchers have unveiled a promising breakthrough that could
transform the landscape of nonsurgical periodontal therapy. This innovative
investigation delves into the clinical efficacy of melatonin supplementation as
a host modulation agent in diabetic patients with periodontitis, providing a
unique perspective on its potential as a therapeutic adjunct.

The study results were published in the Journal of Periodontology. 

Diabetes mellitus (DM) has long been
associated with an exaggerated inflammatory response, exacerbating periodontal
tissue destruction. Literature shows that the application of host modulation
agents to enhance nonsurgical periodontal therapy in individuals with diabetes
is an actively researched area. Hence, researchers conducted a study to
investigate the clinical efficacy of melatonin supplementation and shed light
on its underlying biological mechanisms by examining fundamental markers.

The randomized controlled,
single-blind study involved 55 diabetic patients with periodontitis, with 27
undergoing full-mouth scaling and root planing (fmSRP) alone and 28 receiving
melatonin supplementation (6 mg daily for 30 days) in addition to fmSRP (full-mouth
scaling and root planing plus melatonin, fmSRP-mel). The impact of melatonin
was assessed clinically and biochemically through the analysis of gingival
crevicular fluid RANKL, OPG, MMP-8, and serum IL-1β levels at the 3rd and 6th
months.

Findings:

  • Results from the study indicated that
    melatonin, administered in tablet form at 6 mg daily for 30 days, did not
    induce any local or systemic side effects.
  • FmSRP alone demonstrated a significant
    reduction in serum IL-1β levels, pocket depths, gingival inflammation, and
    gingival crevicular fluid RANKL and MMP-8 levels (p < 0.05).
  • Interestingly, melatonin supplementation
    led to a more pronounced decrease in bleeding and pocket depth scores during
    probing, particularly at the 3-month mark (p < 0.05).
  • Furthermore, RANKL and MMP-8 levels
    exhibited a significant reduction at 3 months, while IL-1β levels decreased at
    6 months compared to the control group (p < 0.05).
  • Notably, OPG levels were
    not significantly affected by the treatments (p > 0.05).

In conclusion, melatonin, as
a host modulation agent, demonstrated a significant enhancement in the clinical
efficacy of fmSRP. The observed reduction in periodontal inflammation and
pocket depths is attributed to melatonin’s marked suppression of RANKL-associated
osteoclastogenesis and extracellular matrix damage. This breakthrough offers a
promising avenue for improved periodontal treatment outcomes in diabetic
individuals, showcasing melatonin’s potential as a therapeutic adjunct in
managing periodontitis in this specific patient population.                         

Further reading: Melatonin supports nonsurgical periodontal treatment in patients with Type 2 diabetes mellitus and periodontitis: A randomized clinical trial. Doi: https://doi.org/10.1002/JPER.23-0335

Powered by WPeMatico